SWOG clinical trial number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Open
Phase
Abbreviated Title
Testing whether high dose chemotherapy and infusion of the patients’ own stem cells improves survival in patients with Peripheral T-cell Lymphoma who achieved a complete remission at the end of the initial chemotherapy
Status Notes
This study is active in SWOG as of January 30, 2025
Activated
01/30/2025
Research committees
Lymphoma
Eligibility Criteria Expand/Collapse
Please see eligibility criteria in protocol on https://ctsu.cancer.gov/.
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
37%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
14%
Open
Phase